PIN Pharma to Present at 2016 New England Venture Summit

NEW YORK--()--PIN Pharma, a pre-IND immunotherapy company focused on modulating the immune system in oncology, today announced it will be presenting at the 2016 New England Venture Summit on Wednesday, December 7th at the Hilton in Dedham, Massachusetts.

About PIN Pharma, Inc.

PIN Pharma is a pre-IND stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants). The lead compound PIN-2 is a first-in-class, novel, next-generation engineered peptide that empowers the immune system in vivo. The Company’s technology primes the innate immune system to modulate adaptive immunity thereby generating and expanding antigen-specific cytotoxic T-cells in vivo. The company is advancing PIN-2 to the clinic early first quarter 2017.


For more information about PIN Pharma and PIN-2, contact Mark Smith, CBO ( or Colin Bier, CEO ( at PIN Pharma, Inc., 3960 Broadway, Suite 620, New York, NY, or call 212-543-2583.


PIN Pharma, Inc.
Mark Smith, CBO, 212-543-2583
Colin Bier, CEO, 212-543-2583

Recent Stories

RSS feed for PIN Pharma, Inc.